The company reported Q1 18 numbers which were below our estimates as well as market consensus. North America, Germany and Belgium & the Netherlands, accounting for half of its revenue (approximately), remained either in line or surpassed its projected growth, whereas France remained subdued and the UK & Ireland recorded negative growth. The company continues with its shopping spree, adding further to its execution risk. We have revised our estimate downward, changing our recommendatio
26 Apr 2018
It’s all about acquisitions
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
It’s all about acquisitions
Eurofins Scientific SE (ESF:WBO) | 0 0 1.6% | Mkt Cap: 8,723m
- Published:
26 Apr 2018 -
Author:
Ankush Kathuria -
Pages:
3
The company reported Q1 18 numbers which were below our estimates as well as market consensus. North America, Germany and Belgium & the Netherlands, accounting for half of its revenue (approximately), remained either in line or surpassed its projected growth, whereas France remained subdued and the UK & Ireland recorded negative growth. The company continues with its shopping spree, adding further to its execution risk. We have revised our estimate downward, changing our recommendatio